G-BA has identified an Evidence for substantial Additional Benefit for Janssen's Imbruvica (R) in combination with Rituximab in non-pretreated CLL

[Anonymous]

ONCOLOGY RESEARCH AND TREATMENT, 2021; 44 (6): 364

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索